Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey

Ilhan Satman; Hayley Bennett; Candeger Yilmaz; Sazi Imamoglu; Goksun Ayvaz; Abdurrahman Comlekci; Demet Ozkaya; Toros Sahin

doi:10.36469/9858

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:31985/feed

ISSN 2327-2236

Endocrine Diseases

Vol. 1, Issue 2, 2013

August 15, 2013 EDT

Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey

Ilhan Satman, Hayley Bennett, Candeger Yilmaz, Sazi Imamoglu, Goksun Ayvaz, Abdurrahman Comlekci, Demet Ozkaya, Toros Sahin,

turkeytype 2 diabetesnph insulininsulin glarginecost effectiveness

ccby-4.0

• https://doi.org/10.36469/9858

JHEOR

Satman I, Bennett H, Yilmaz C, et al. Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey. JHEOR. 2013;1(2):108-122. doi:10.36469/9858

View more stats